Anne-Ségolène Cottereau researcher ORCID ID = 0000-0002-4805-4564
Cottereau, Anne-Ségolène, 1988-...
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 867144647714370837470 (Personal)
Permalink: http://viaf.org/viaf/867144647714370837470
Preferred Forms
4xx's: Alternate Name Forms (1)
Works
| Title | Sources |
|---|---|
| Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. |
|
| Brain (18)F-FDG, (18)F-Florbetaben PET/CT, (123)I-FP-CIT SPECT and Cardiac (123)I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease |
|
| Brain 18F-FDG PET Metabolic Abnormalities in Patients with Long-Lasting Macrophagic Myofascitis |
|
| Development and clinical applications of new 18F-FDG PET biomarkers in lymphoma |
|
| Early Phase 99Tc-HMDP Scintigraphy for the Diagnosis and Typing of Cardiac Amyloidosis |
|
| Early-phase myocardial uptake intensity of 99mTc-HMDP vs 99mTc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis. |
|
| FDG-PET in PMBCL: which heterogeneity? |
|
| Interim PET in Hodgkin Lymphoma: Is It So Useless? |
|
| Interim PET in lymphoma: from Deauville to Peking criteria. On the road, again…. |
|
| Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma? |
|
| MFN2-associated lipomatosis: Clinical spectrum and impact on adipose tissue |
|
| Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCL-Response. |
|
| PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma. |
|
| Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. |
|
| Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma. |
|
| Predictive value of (18)F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial |
|
| Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study. |
|
| Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). |
|
| Prolonged response to 177Lu-DOTATATE therapy of a bone marrow infiltration in a refractory thymic neuro endocrine tumor |
|
| Reply to H.J.A. Adams et al and E. Laffon et al |
|
| Report of the 6th International Workshop on PET in lymphoma |
|
| "Staging, restaging and treatment response assessment" in lymphomas: what we should know. |
|
| <sup>18</sup>F-FDG PET maximum intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients |
|
| TEP/TDM et récidive biologique d’adénocarcinome prostatique : apport du 68 Ga-PSMA-11 lorsque la 18 F-fluorocholine n’est pas contributive |
|
| Valeur pronostique du volume métabolique tumoral total mesure sur la TEP/TDM initiale associe au profil d’expression génique dans les lymphomes B diffus à grandes cellules |
|
| Visualization of Macroprolactinoma by F-Fluorocholine PET/CT in a Patient With Multiple Endocrine Neoplasia Type 1 |
|
| Whole-Body Diffusion-weighted MR Imaging of Iron Deposits in Hodgkin, Follicular, and Diffuse Large B-Cell Lymphoma |
|
